Clinical Trial Update: Indoor Woodsmoke PM and Asthma [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating the effects of indoor woodsmoke particulate matter exposure on asthma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Snippet

Sponsor: National Institute of Environmental Health Sciences (NIEHS) | Conditions: Asthma | Phase 3 | Status: COMPLETED